---
run_id: halo-evidence-vs-diagnosis-validation-v11-vanilla-long-prompt-01
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
model_condition: vanilla_long_prompt
run_number: 1
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 104
prompt_source: condition packet (vanilla_long_prompt) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 18fa1d51f6167dbbf1f7ece676734d5cdb459384bca25e1508dd96cd4745e42d
source_packet: a neutral equal-length filler plus transition, then the frozen Advisor prompt; no substrate artifact - see run-packet.md
source_packet_sha256: b2788902c52d3bd202aee721889f5170e506802736ec9b70be6e014d6c8ff138
condition_packet_sha256: b2788902c52d3bd202aee721889f5170e506802736ec9b70be6e014d6c8ff138
output_file: model-outputs/vanilla_long_prompt.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla_long_prompt (run 01)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v11-v1`, condition `vanilla_long_prompt`, run 1 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 104, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

**Why:**
Your current success is "entangled"—the positive financial metrics are likely skewed by temporary pricing bundles and the usage metrics are inflated by managers running samples rather than adjusters managing live claims. You have a critical "black box" problem: you know that front-line adjusters abandon the tool and health-liability users cannot explain its logic, but you don't know *why* the recommendations are being overridden or ignored. The Claim File Review is the only proposal that provides qualitative, ground-truth evidence of product-market fit. It bypasses the "enthusiastic" but biased sales feedback and reveals whether SignalPath actually solves a workflow problem or is simply a novelty that managers like but practitioners find useless.

**The strongest reason against it:**
This approach is slow and manual compared to the Usage Quality Sprint. It provides a snapshot of specific files rather than a continuous stream of behavioral data, meaning you risk making a strategic decision based on a small sample size while the board's budget window closes.

**Observable evidence that would change my mind:**
If the "wrong recommendation" tickets in the training channel spike significantly or if the regional carriers who are removing SignalPath provide specific, documented feedback that the tool's output is fundamentally inaccurate (rather than just "hard to explain"), I would pivot to the **Usage Quality Sprint**. This would indicate that the problem is a technical failure of the recommendation engine (requiring rapid iteration) rather than a workflow/enablement failure (requiring the deep-dive review).
